{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:04:41Z","timestamp":1774937081220,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.biopha.2015.10.028","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T14:05:41Z","timestamp":1447855541000},"page":"127-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl \u03b2-cyclodextrin formulation and pharmacokinetics via intravenous route"],"prefix":"10.1016","volume":"76","author":[{"given":"Kaluvu","family":"Balaraman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nashira Campos","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fathi","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00ebl","family":"Vacus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Cojean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Pomel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Bories","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Figad\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ventikasamy","family":"Kesavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe M.","family":"Loiseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2015.10.028_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/2229-5070.129142","article-title":"Drug resistance in leishmaniasis: newer developments","volume":"4","author":"Mohapatra","year":"2014","journal-title":"Trop. Parasitol."},{"key":"10.1016\/j.biopha.2015.10.028_bib0010","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1128\/AAC.42.2.352","article-title":"Mechanism of amphotericin B resistance in Leishmania donovani promastigotes","volume":"42","author":"Mbongo","year":"1998","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.biopha.2015.10.028_bib0015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0924-8579(03)00125-0","article-title":"Characterisation of Leishmania donovani promastigotes r\u00e9sistant to hexadecylphosphocholine (miltefosine)","volume":"22","author":"Seifert","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2015.10.028_bib0020","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1128\/AAC.00030-11","article-title":"Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani","volume":"56","author":"Purkait","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2015.10.028_bib0025","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3201\/eid1804.110841","article-title":"Leishmania r\u00e9sistance to miltefosine associated with genetic marker","volume":"18","author":"Cojean","year":"2012","journal-title":"Emerg. Infect Dis."},{"key":"10.1016\/j.biopha.2015.10.028_bib0030","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/AAC.37.4.859","article-title":"2-substituted quinoline alkaloids as potential antileishmanial drugs","volume":"37","author":"Fournet","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2015.10.028_bib0035","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1128\/AAC.40.11.2447","article-title":"In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis","volume":"40","author":"Fournet","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2015.10.028_bib0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1051\/parasite\/2011184333","article-title":"Antileishmanial activity of a formulation of 2-n-propylquinoline by oral route in mice model","volume":"18","author":"Campos-Vieira","year":"2011","journal-title":"Parasite"},{"key":"10.1016\/j.biopha.2015.10.028_bib0045","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1016\/j.bmc.2003.09.007","article-title":"Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral coinfections","volume":"11","author":"Fakhfakh","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2015.10.028_bib0050","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1128\/AAC.49.12.4950-4956.2005","article-title":"Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and viceral leishmaniasis","volume":"49","author":"Nakayama","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2015.10.028_bib0055","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.biopha.2007.02.001","article-title":"In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline agaisnt Leishmania donovani","volume":"61","author":"Nakayama","year":"2007","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2015.10.028_bib0060","first-page":"684","article-title":"Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials","volume":"62","author":"Campos-Vieira","year":"2008","journal-title":"Biochem. Pharmacother."},{"key":"10.1016\/j.biopha.2015.10.028_bib0065","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.biopha.2007.03.004","article-title":"Antileishmanial 2-substituted quinolines: in vitro behaviour towards biological components","volume":"61","author":"Desrivot","year":"2007","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2015.10.028_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2015.10.028_bib0075","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0020-7519(00)00053-9","article-title":"Therapeutic \u00e9valuation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis","volume":"30","author":"Cauchetier","year":"2000","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.biopha.2015.10.028_bib0080","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2174\/1568026613666131219125135","article-title":"Progress in developing amphiphilic cyclodextrin-based nanodevices for drug delivery","volume":"14","author":"Yameogo","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.biopha.2015.10.028_bib0085","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0378-4347(98)00219-9","article-title":"Determination of 2-n-propylquinoline in mouse plasma and liver by high-performance liquid chromatography","volume":"714","author":"Iglarz","year":"1998","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.biopha.2015.10.028_bib0090","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.bmcl.2014.03.065","article-title":"Design, synthesis, ADME characterization and antileishmanial evaluation of novel substituted quinoline analogs","volume":"24","author":"Gopinath","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.biopha.2015.10.028_bib0095","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ejmech.2013.08.028","article-title":"Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents","volume":"69","author":"Gopinath","year":"2013","journal-title":"Eur. J. Med. Chem."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332215002462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332215002462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:59:51Z","timestamp":1760093991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332215002462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":19,"alternative-id":["S0753332215002462"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2015.10.028","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl \u03b2-cyclodextrin formulation and pharmacokinetics via intravenous route","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2015.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}